Nitazoxanide (Alinia)
Prior authorization form and clinical criteria for coverage of nitazoxanide (Alinia) including required prescriber qualifications, diagnoses, documentation, and quantity/age limits. Applies to pharmacy benefit requests submitted to AvMed.
No material clinical/coverage changes
Coverage Summary
Prior authorization is required for nitazoxanide (Alinia) and is limited to confirmed infections with Giardia lamblia or Cryptosporidium parvum. Approval requires that the prescriber be a gastroenterologist or infectious disease specialist and that lab test results confirming the diagnosis be submitted. Age and quantity limits apply: children 1–11 years: maximum 60 mL (1 bottle); children and adults ≥12 years: maximum 6 tablets; and a maximum of 1 approval per lifetime.
Clinical Criteria for Approval
Clinical Criteria for Approval
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.